1BT Intrinsic Valuation and Fundamental Analysis - Enlivex Ltd

Watchlist Manager

Watchlist

Price: 0.155 EUR -0.64% Market Closed

Market Cap: €3.2m

E	Enlivex Ltd F:1BT	IL
A	Abercrombie & Fitch Co XMUN:AFT	US
	Altamir SCA PAR:LTA	FR

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value for Enlivex Ltd.

Do our valuations actually work? See backtest results .

Fundamental Analysis

What Enlivex Does

Biotechnology Health Care

Enlivex Therapeutics is a clinical-stage biotechnology company that develops cell-based therapies for severe inflammatory diseases. Its main program is built around a treatment called Allocetra, which uses immune cells to help reset an overactive immune response. The company is trying to turn this approach into medicines for conditions where the body’s own inflammation becomes harmful, such as sepsis and other acute disorders.

Headquarters: Israel IL
Employees: 34
IPO date: Jul 30, 2014

Read the full company overview

How Enlivex makes money

Cell therapy development

Enlivex Therapeutics develops cell-based treatments that are designed to calm harmful immune responses. Its work centers on taking cells from donors, processing them, and testing them as therapies for conditions where the immune system becomes overactive.

Customers: The company does not sell products to everyday consumers. Its buyers are hospitals, doctors, and research partners only when its therapies are approved or used in clinical settings, and it also works with regulators and trial sites during development.
Revenue Model: Enlivex is mainly a research-stage biotech, so it expects to make money by licensing its therapy programs, partnering with larger drug companies, or selling approved treatments if any reach the market.

View Company Overview